Luca Visani

Clinical Oncologist - Clinical Trials Coordinator Breast Unit AOU Careggi

[Paolo Tarantino @PTarantinoMD]

Good news to start the year. In a RW cohort of 67 patients receiving concomitant T-DXd and RT (within 10 days - 55% brain), the risk of AEs or discontinuation was comparable to patients not receiving RT. Only one case of symptomatic radionecrosis (1.5%). https://t.co/FzQ0ETM5aB

[Icro Meattini @Icro_Meattini]

ASCENT-03 support sacituzumab govitecan (SG) as a potential new standard for previously untreated mTNBC not candidate for a PDL1 inhibitor
#ESMO25 @OncoAlert #OncoAlert

And another @NEJM publication 💪🏼
@JavierCortesMD

[Icro Meattini @Icro_Meattini]

DESTINY-Breast05 investigators deserve congratulations once again - for collecting data on sequential and concurrent RT with T-DXd vs T-DM1, including CT imaging and ILD/pneumonitis quality data

Concomitant treatment safe

#ESMO25 @OncoAlert #OncoAlert #BreastCancer #radonc

[Icro Meattini @Icro_Meattini]

TROPION-Breast02 met both primary endpoints OS and PFS in mTNBC (immunotherapy not an option) in favour of Dato-DXd #ESMO25

@OncoAlert #OncoAlert

[Icro Meattini @Icro_Meattini]

Welcome back @myESMO #ESTRO25
Stronger, together 💪

👉 Chairing with @curijoey ESMO President Elect - the ESTRO-ESMO Symposium on Integration of Novel Systemic Therapies into #Radiotherapy (3 May 2025)

https://t.co/kZnNWzvZq7

@ESTRO_RT @OncoAlert #OncoAlert #medonc #radonc

[Luca Visani @LucaVisani2]

Esclusive RT vs ET for older women >70y with pT1N0 luminal A tumors. Less impact on HRQoL with RT at the first interim analysis. Wonderful presentation by @Icro_Meattini, very well done! Proud to be part of this project. See the concomitant publication on Lancet Oncology! #SABCS

[Icro Meattini @Icro_Meattini]

Association between risk reducing surgeries and survival in young BRCA carriers with #BreastCancer

Accumulating crucial evidence presented by amazing Prof Matteo Lambertini #SABCS24 @matteolambe

@OncoAlert #OncoAlert

[Luca Visani @LucaVisani2]

EMBER-3: imlunestrant alone or imlunestrant plus abemaciclib vs fulvestrant in patients previously treated with ET (prior CDK4/6i in 60% of patients). Imlunestrant effective as monotherapy in ESR1m patients, in combination with abema benefit showed for all patients #SABCS24

[EORTC Breast Cancer Group @EORTC_BCG]

Great @EORTC_BCG Autumn Meeting in Paris @institut_curie ! 2 days of insightful presentations and productive discussions on current and future activities of the group! @MIgnatiadis @EtienneB66 @c_sotiriou @EORTC @OncoAlert #breastcancer #bcsm

[Giulio Francolini @GiulioFrancoli1]

Very Happy to present early results from STARR trial (NCT05455736) at ASTRO! #ASTRO24 ,@dicataldovanes1 ,@PietroGarlatti

[Luca Visani @LucaVisani2]

Multicentre retrospective study comparing safety outcomes of BC patients treated with T-DXd with or without concomitant RT (379P). No impact on acute toxicity development and T-DXd discontinuation ‼️@Icro_Meattini @i_ratosa @CarlottaB @VSalvestrini @andMORand #ESMO2024 #ESMO24

[Icro Meattini @Icro_Meattini]

Neoadjuvant pembrolizumab or placebo plus chemotherapy for triple negative #breastcancer - Overall Survival results from the KEYNOTE-522 phase 3 trial #ESMO24

@NEJM @myESMO
#OncoAlert @OncoAlert

[Hope Rugo @hoperugo]

#esmo2024 Meghna Trivedi presents results from I-SPY2.2 Dato-DXd plus Durva. This personalized approach to therapy allows optimal efficacy with reduced toxicity in 50% with most achieving pCR without anthracyclines. Imp model for trials ⁦@OncoAlert⁩

[Luca Visani @LucaVisani2]

Another important confirmation that ER-low breast cancer should be treated as triple negative! #ESMO2024 #ESMO24 #breastcancer

[Sara Tolaney @stolaney1]

Registry of stage 1 TNBC (>1100 pts)
pCR: 57.3%
pCR associated w/ better OS (HR 0.29)

@OncoAlert #bcsm #ESMO24

[Luca Visani @LucaVisani2]

Magnitude of benefit in iDFS with adjuvant ribociclib plus NSAI seems to be higher for younger patients. #ESMO2024 #ESMO24 #breastcancer

[Luca Visani @LucaVisani2]

Confirmed importance of ovarian suppression (especially plus AI) for premenopausal HR+/HER2+ patients, irrespectively of adjuvant trastuzumab administration in the HERA trial #ESMO2024 #ESMO24 #breastcancer

[Giulio Francolini @GiulioFrancoli1]

PERSIAN trial will offer the unique opportunity to evaluate SBRT in a selected cohort of oligometastatic metachronous patients. It reached 30% of planned accrual! @dicataldovanes1,@PietroGarlatti,@ALESSIOBRUNI10
https://t.co/o1OSlKNrvJ

[Matteo Lambertini, MD PhD @matteolambe]

Presented today at #SABCS23 and published in @JAMA_current results of our study showing the feasibility and safety of #pregnancy after #BreastCancer in young #BRCA carriers

@OncoAlert @SABCSSanAntonio @AACR @UniGenova @SanMartino_Ge #bcsm

Link here:
https://t.co/PqAAhVq2bO

[Oncoinfo @Oncoinfo_it]

#SABCS23 | @matteolambe: supporting data for TD-Xd intracranial activity in both stable and active brain metastasis and in the leptomeningeal disease.

#breastcancer #trastuzumabderuxtecan @SanMartino_Ge @ArmandOrlandi @BianchiniGP